1
|
Rivalta B, Attardi E, Cifaldi C, Rosti V, Pacillo L, Hajrullaj H, Di Cesare S, Amodio D, Algeri M, Luciani M, Barzaghi F, Finocchi A, Di Matteo G, Aiuti A, Locatelli F, Voso MT, Palumbo G, Cancrini C. Natural history of Ras-associated autoimmune leukoproliferative disorder: A 20-year follow-up of a NRAS-mutated patient excluding a malignant progression. Br J Haematol 2024; 204:e6-e10. [PMID: 37921255 DOI: 10.1111/bjh.19150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Accepted: 09/28/2023] [Indexed: 11/04/2023]
Affiliation(s)
- B Rivalta
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
| | - E Attardi
- PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - C Cifaldi
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
| | - V Rosti
- Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
| | - L Pacillo
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
| | - H Hajrullaj
- PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - S Di Cesare
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - D Amodio
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - M Algeri
- Department of Pediatric Hemato-Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
| | - M Luciani
- Department of Pediatric Hemato-Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
| | - F Barzaghi
- Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - A Finocchi
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - G Di Matteo
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - A Aiuti
- Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - F Locatelli
- Department of Pediatric Hemato-Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy
| | - M T Voso
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
| | - G Palumbo
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- Department of Pediatric Hemato-Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
| | - C Cancrini
- Research Unit of Primary Immunodeficiencies, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, Scientific Institute for Research and Healthcare (IRCCS), Rome, Italy
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| |
Collapse
|
2
|
Rago A, Palumbo G, Tordi A, Bianchi S, Offidani M, di Toritto TC. A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma. Ann Hematol 2023; 102:2977-2978. [PMID: 37432414 DOI: 10.1007/s00277-023-05319-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 06/12/2023] [Indexed: 07/12/2023]
Affiliation(s)
- A Rago
- Haematology Unit, ASL ROMA 1, Rome, Italy.
| | - G Palumbo
- Department of Translational and Precision Medicine, Haematology, A.O.U Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
| | - A Tordi
- Haematology Unit, ASL ROMA 1, Rome, Italy
| | - S Bianchi
- Department of Translational and Precision Medicine, Haematology, A.O.U Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
| | | | | |
Collapse
|
3
|
Morabito A, Mercadante E, Muto P, Palumbo G, Manzo A, Montanino A, Sandomenico C, Sforza V, Costanzo R, Damiano S, La Manna C, Martucci N, La Rocca A, De Luca G, Totaro G, De Cecio R, Picone C, Piccirillo MC, De Feo G, Tracey M, D'Auria S, Normanno N, Capasso A, Pascarella G. Risk Management Activities in a Lung Cancer Multidisciplinary Team at a Comprehensive Cancer Center: Results of a Prospective Analysis. JCO Oncol Pract 2023; 19:e315-e325. [PMID: 36383923 DOI: 10.1200/op.22.00358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
PURPOSE The objective of the study was to highlight sources of harm that could negatively affect the lung cancer multidisciplinary team (MDT) activities to reduce the level of risk of each factor. METHODS A modified Delphi approach was used by a board of multi-health care professionals of the lung cancer MDT to identify the main processes, subprocesses, and risk factors of the multidisciplinary pathway of patients with lung cancer. A semiquantitative matrix was built with a five-point scale for probability of harm (likelihood) and severity of harm (consequences) according to the international risk management standards (ISO 31000-2018). The risk level was calculated by multiplying likelihood × consequences. Mitigation strategies have been identified and applied by the MDT to reduce risks to acceptable levels. RESULTS Three main processes (outpatient specialist visit, MDT discussion, and MDT program implementation), eight related subprocesses, and 16 risk factors were identified. Four risk factors (25%) were related to outpatient specialist visit, seven (43.75%) to case discussion, and five (31.25%) to program implementation. Overall, two risk factors were assigned a low-risk level (12.5%), 11 a moderate-risk level (68.75%), one (6.25%) a high-risk level, and two (12.5%) a very high-risk level. After the implementation of mitigation measures, the new semiquantitative risk analysis showed a reduction in almost all hazardous situations: two risk factors (12.5%) were given a very low level, six (37.5%) a low level, seven (43.75%) a moderate level, and one (6.25%) a very high level. CONCLUSION An interdisciplinary risk assessment analysis is applicable to MDT activities by using an ad hoc risk matrix: if the hazard is identified and monitored, the risk could be reduced and managed in a short time.
Collapse
Affiliation(s)
- Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Edoardo Mercadante
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Paolo Muto
- Radiotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale," IRCCS, Naples, Italy
| | - Giuliano Palumbo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Simona Damiano
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS "Fondazione G. Pascale," Napoli, Italy
| | - Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Nicola Martucci
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Antonello La Rocca
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Giuseppe De Luca
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Giuseppe Totaro
- Radiotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale," IRCCS, Naples, Italy
| | - Rossella De Cecio
- Pathology, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Carmine Picone
- Radiology, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | | | - Gianfranco De Feo
- Scientific Directorate, Istituto Nazionale Tumori "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Maura Tracey
- Rehabilitative Medicine Unit, Istituto Nazionale Tumori "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Stefania D'Auria
- Department of Health Management, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Nicola Normanno
- Scientific Directorate, Istituto Nazionale Tumori "Fondazione G. Pascale," IRCCS, Napoli, Italy.,Cellular Biology and Biotherapy, Istituto Nazionale Tumori, "Fondazione G. Pascale," IRCCS, Napoli, Italy
| | - Arturo Capasso
- Wroclaw School of Banking Wyższa Szkoła Bankowa, Wrocalw, Poland
| | - Giacomo Pascarella
- Scientific Directorate, Istituto Nazionale Tumori "Fondazione G. Pascale," IRCCS, Napoli, Italy
| |
Collapse
|
4
|
Manzo A, Sforza V, Carillio G, Palumbo G, Montanino A, Sandomenico C, Costanzo R, Esposito G, Laudato F, Mercadante E, La Manna C, Muto P, Totaro G, De Cecio R, Picone C, Piccirillo MC, Pascarella G, Normanno N, Morabito A. Lurbinectedin in small cell lung cancer. Front Oncol 2022; 12:932105. [PMID: 36110944 PMCID: PMC9469650 DOI: 10.3389/fonc.2022.932105] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Accepted: 08/08/2022] [Indexed: 11/25/2022] Open
Abstract
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works by inhibiting oncogenic transcription and promoting apoptosis in tumor cells. A phase II basket trial demonstrated the activity of lurbinectedin at the dose of 3.2 mg/m2 in patients with SCLC who had failed a previous chemotherapy, with a response rate of 35.2%, a median progression-free survival (mPFS) of 3.5 months, and a median overall survival (mOS) of 9.3 months. Common severe adverse events (grades 3–4) were hematological disorders, including anemia (9%), leukopenia (29%), neutropenia (46%), and thrombocytopenia (7%). On the basis of the positive results of this phase II study, on June 2020, lurbinectedin was approved by the Food and Drug Administration as second line for SCLC patients in progression on or after platinum-based therapy. The subsequent phase III trial comparing the combination of lurbinectedin plus doxorubicin vs. CAV (cyclophosphamide, Adriamycin, and vincristine) or topotecan did not demonstrate an improvement in overall survival, although the experimental arm showed a superior safety profile. Combinations of lurbinectedin with other drugs, cytotoxic agents and immune checkpoint inhibitors, are currently under investigation. The results of these studies should better define the optimal clinical application of lurbinectedin.
Collapse
Affiliation(s)
- Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Guido Carillio
- Department of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - Giuliano Palumbo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | | | - Francesca Laudato
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Edoardo Mercadante
- Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G. Pascale” – IRCCS, Napoli, Italy
| | - Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G. Pascale” – IRCCS, Napoli, Italy
| | - Paolo Muto
- Radiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Naples –, Italy
| | - Giuseppe Totaro
- Radiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Naples –, Italy
| | - Rossella De Cecio
- Pathology, Istituto Nazionale Tumori, “Fondazione G. Pascale” – IRCCS, Napoli, Italy
| | - Carmine Picone
- Radiology, Istituto Nazionale Tumori, “Fondazione G. Pascale” – IRCCS, Napoli, Italy
| | | | - Giacomo Pascarella
- Scientific Directorate, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Napoli, Italy
| | - Nicola Normanno
- Scientific Directorate, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Napoli, Italy
- Cellular Biology and Biotherapy, Istituto Nazionale Tumori, “Fondazione G. Pascale” – IRCCS, Napoli, Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Napoli, Italy
- *Correspondence: Alessandro Morabito, ;
| |
Collapse
|
5
|
Mele A, Prete E, Citiso S, Mele G, Pastore D, Sgherza N, Curci P, Musto P, Falcone AP, Cascavilla N, Germano C, Giuseppe T, Reddiconto G, Di Renzo N, Palazzo G, Mazza P, Rossini B, Guarini A, Palumbo G, Melillo LMA, Pavone V. PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP). Hemasphere 2022. [PMCID: PMC9431550 DOI: 10.1097/01.hs9.0000850896.11254.d1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Mele G, Cascavilla N, Di Renzo N, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Palazzo G, Palumbo G, Reddiconto G, Rossini B, Specchia G, Musto P, Pastore D. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'. Ann Hematol 2022; 101:1727-1739. [PMID: 35587825 DOI: 10.1007/s00277-022-04857-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 04/24/2022] [Indexed: 12/01/2022]
Abstract
We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with daratumumab in combination with bortezomib or lenalidomide as salvage therapy at 9 haematological centres in Puglia. Choice of both regimens was based on previous treatment and/or physicians' preference. Considering the under-representation of older patients (very old patient ≥ 80 years) in clinical trials and the prognostic and predictive importance and value of frailty status, here, we further characterised the patient cohort by age. The overall response rate (ORR) was generally lower than what was previously reported in the CASTOR (ORR 72.6% vs 85%) and POLLUX (ORR 86.5% vs 93%) trials. The lower ORR in our analysis compared to the CASTOR and POLLUX trials could be related to a less selected population. Similarly, amongst very old patients, the ORR was encouraging: ORR to treatment with DVd (daratumumab + bortezomib + dexamethasone) was 66.7%, and ORR to treatment with DRd (daratumumab + lenalidomide + dexamethasone) was 92.3%. Median TTP (time to progression) was 10.8 months (1-year TTP: 44.7%; 2-year TTP: 25.3%) in the DVd group; median TTP was not reached in the DRd group (1-year TTP: 82.7%; 2-year TTP: 71.4%). Median OS (overall survival) was not reached either in the DRd group (1-year OS: 85.9%; 2-year OS: 73.7%) or the DVd group (1-year OS: 70.2%; 2-year OS: 58.9%).
Collapse
Affiliation(s)
- G Mele
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy.
| | - N Cascavilla
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - N Di Renzo
- Haematology, Ospedale V. Fazzi, Lecce, Italy
| | - A Guarini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - P Mazza
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - L Melillo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | - V Pavone
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Tarantini
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - P Curci
- University of Bari Medical School, Policlinico, Bari, Italy
| | - A P Falcone
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - C Germano
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - A Mele
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Palazzo
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - G Palumbo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | | | - B Rossini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - G Specchia
- University of Bari Medical School, Policlinico, Bari, Italy
| | - P Musto
- University of Bari Medical School, Policlinico, Bari, Italy
| | - D Pastore
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy
| |
Collapse
|
7
|
Morabito A, Manzo A, Montanino A, Rachiglio AM, Sforza V, Pasquale R, Costanzo R, Maiello MR, Sandomenico C, Gallo M, Palumbo G, De Luca A, La Rocca A, Martucci N, De Cecio R, Picone C, Lastoria S, Normanno N. Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion. Oncologist 2022; 27:7-12. [PMID: 35305107 PMCID: PMC8842466 DOI: 10.1093/oncolo/oyab002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Accepted: 11/22/2021] [Indexed: 12/26/2022] Open
Abstract
Increasing evidence suggests that liquid biopsy might play a relevant role in the management of metastatic non-small cell lung cancer (NSCLC) patients. Here, we show how the Molecular Tumor Board (MTB) in our cancer center employed liquid biopsy to support therapeutic decisions in a patient with NSCLC carrying a rare EGFR mutation. A 44-year-old woman, never-smoker with an EGFR, ALK, and ROS1-negative lung adenocarcinoma and multiple brain metastases received systemic therapy and surgery before being referred to our Institute. The MTB suggested NGS testing of tumor biopsy that revealed a rare exon-20 EGFR insertion (p.His773dup; c.2315_2316insCCA) and EGFR amplification. The MTB recommended treatment with erlotinib and follow-up with liquid biopsy, by using both cell-free DNA (cfDNA) and circulating tumor cells (CTCs). An increase of EGFR mutation levels in cfDNA revealed resistance to treatment about 6 months before clinical progression. Extremely low levels of EGFR p.T790M were detected at progression. Based on preclinical data suggesting activity of osimertinib against EGFR exon-20 insertions, the MTB recommended treatment with brain and bone radiotherapy and osimertinib. A dramatic reduction of EGFR mutation levels in the cfDNA was observed after 4 weeks of treatment. The PET scan demonstrated a metabolic partial remission that was maintained for 9 months. This case supports the evidence that liquid biopsy can aid in the management of metastatic NSCLC. It also suggests that treatment with osimertinib might be a therapeutic option in patients with EGFR exon-20 insertions when a clinical trial is not available.
Collapse
Affiliation(s)
- Alessandro Morabito
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Anna Manzo
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Agnese Montanino
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Anna Maria Rachiglio
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Vincenzo Sforza
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Raffaella Pasquale
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Raffaele Costanzo
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Monica R Maiello
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Claudia Sandomenico
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Marianna Gallo
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Giuliano Palumbo
- Thoracic Medical Oncology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Antonella De Luca
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Antonello La Rocca
- Thoracic Surgery Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Nicola Martucci
- Thoracic Surgery Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Rossella De Cecio
- Surgical Pathology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Carmine Picone
- Radiology Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Secondo Lastoria
- Nuclear Medicine Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| | - Nicola Normanno
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - “Fondazione G. Pascale”, Napoli, Italy
| |
Collapse
|
8
|
Portella L, Guardascione G, Bertolini G, Ieranò C, D'Alterio C, Rea G, Santagata S, Trotta A, Camerlingo R, Scarpa E, Cecere S, Ottaiano A, Palumbo G, Morabito A, Pacelli R, Pignata S, Scala S. 1796P CXCL12-loaded-hydrogel (CLG) based 'pseudo niche': A new device for CTCs capturing and characterization. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Cascetta P, Sforza V, Manzo A, Carillio G, Palumbo G, Esposito G, Montanino A, Costanzo R, Sandomenico C, De Cecio R, Piccirillo MC, La Manna C, Totaro G, Muto P, Picone C, Bianco R, Normanno N, Morabito A. RET Inhibitors in Non-Small-Cell Lung Cancer. Cancers (Basel) 2021; 13:cancers13174415. [PMID: 34503226 PMCID: PMC8431193 DOI: 10.3390/cancers13174415] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 08/12/2021] [Accepted: 08/30/2021] [Indexed: 11/16/2022] Open
Abstract
RET rearrangements are observed in 1-2% of non-small-cell lung cancer (NSCLC) patients and result in the constitutive activation of downstream pathways normally implied in cell proliferation, growth, differentiation and survival. In NSCLC patients, RET rearrangements have been associated with a history of non-smoking, a higher rate of brain metastasis at initial diagnosis and a low immune infiltrate. Traditionally, RET fusions are considered mutually exclusive with other oncogenic drivers, even though a co-occurrence with EGFR mutations and MET amplifications has been observed. Cabozantinib, vandetanib and lenvatinib are the first multi-kinase inhibitors tested in RET-rearranged NSCLC patients with contrasting results. More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy rates and good tolerability and they were approved for the treatment of patients with metastatic RET fusion-positive NSCLC on the bases of the results of phase II studies. Two ongoing phase III clinical trials are currently comparing selpercatinib or pralsetinib to standard first line treatments and will definitively establish their efficacy in RET-positive NSCLC patients.
Collapse
Affiliation(s)
- Priscilla Cascetta
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Guido Carillio
- Department of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy;
| | - Giuliano Palumbo
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Giovanna Esposito
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
| | - Rossella De Cecio
- Department of Pathology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy;
| | - Maria Carmela Piccirillo
- Clinical Trials Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy;
| | - Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy;
| | - Giuseppe Totaro
- Department of Radiotherapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (G.T.); (P.M.)
| | - Paolo Muto
- Department of Radiotherapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (G.T.); (P.M.)
| | - Carmine Picone
- Department of Radiology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy;
| | - Roberto Bianco
- Department of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, 80131 Napoli, Italy;
| | - Nicola Normanno
- Cellular Biology and Biotherapy and Scientific Directorate, Istituto Nazionale Tumori, “Fondazione G.Pascale” IRCCS, 80131 Napoli, Italy;
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy; (P.C.); (V.S.); (A.M.); (G.P.); (G.E.); (A.M.); (R.C.); (C.S.)
- Correspondence: or ; Tel.: +39-0815903522; Fax: +39-0817702938
| |
Collapse
|
10
|
Montanino A, Manzo A, Carillio G, Palumbo G, Esposito G, Sforza V, Costanzo R, Sandomenico C, Botti G, Piccirillo MC, Cascetta P, Pascarella G, La Manna C, Normanno N, Morabito A. Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol 2021; 11:655316. [PMID: 34123809 PMCID: PMC8195287 DOI: 10.3389/fonc.2021.655316] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 05/03/2021] [Indexed: 12/22/2022] Open
Abstract
Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS. Instead, disappointing results have been observed with endostar, sunitinib, sorafenib, vandetanib, and thalidomide in combination with chemotherapy in the first-line setting, with sunitinib in the maintenance setting, with sunitinib, cediranib and nintedanib as single agents or ziv-aflibercept in combination with topotecan in second-line setting. Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.
Collapse
Affiliation(s)
- Agnese Montanino
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Anna Manzo
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Guido Carillio
- Department of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - Giuliano Palumbo
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Giovanna Esposito
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Vincenzo Sforza
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Raffaele Costanzo
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Claudia Sandomenico
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Gerardo Botti
- Scientific Directorate, Istituto Nazionale Tumori, "Fondazione G. Pascale" - IRCCS, Naples, Italy
| | - Maria C Piccirillo
- Scientific Department, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS, Naples, Italy
| | | | - Giacomo Pascarella
- Scientific Directorate, Istituto Nazionale Tumori, "Fondazione G. Pascale" - IRCCS, Naples, Italy
| | - Carmine La Manna
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| | - Nicola Normanno
- Scientific Department, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS, Naples, Italy
| | - Alessandro Morabito
- Thoracic Department, Istituto Nazionale Tumori, IRCCS "Fondazione G.Pascale", Naples, Italy
| |
Collapse
|
11
|
Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR. A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Pharmacokinet 2021; 59:207-216. [PMID: 31313068 DOI: 10.1007/s40262-019-00803-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
INTRODUCTION The pharmacokinetics (PK) of the 20S proteasome inhibitor bortezomib are characterized by a large volume of distribution and a rapid decline in plasma concentrations within the first hour after administration. An increase in exposure was observed in the second week of treatment, which has previously been explained by extensive binding of bortezomib to proteasome in erythrocytes and peripheral tissues. We characterized the nonlinear population PK and pharmacodynamics (PD) of bortezomib in children with acute lymphoblastic leukemia. METHODS Overall, 323 samples from 28 patients were available from a pediatric clinical study investigating bortezomib at an intravenous dose of 1.3 mg/m2 twice weekly (Dutch Trial Registry number 1881/ITCC021). A semi-physiological PK model for bortezomib was first developed; the PK were linked to the decrease in 20S proteasome activity in the final PK/PD model. RESULTS The plasma PK data were adequately described using a two-compartment model with linear elimination. Increased concentrations were observed in week 2 compared with week 1, which was described using a Langmuir binding model. The decrease in 20S proteasome activity was best described by a direct effect model with a sigmoidal maximal inhibitory effect, representing the relationship between plasma concentrations and effect. The maximal inhibitory effect was 0.696 pmol AMC/s/mg protein (95% confidence interval 0.664-0.728) after administration. CONCLUSION The semi-physiological model adequately described the nonlinear PK and PD of bortezomib in plasma. This model can be used to further optimize dosing of bortezomib.
Collapse
Affiliation(s)
- Julie M Janssen
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
| | - T P C Dorlo
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
| | - D Niewerth
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
| | - A J Wilhelm
- Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, Amsterdam, The Netherlands
| | - C M Zwaan
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
- Department of Pediatric Oncology/Hematology, Erasmus-MC Sophia Children's Hospital, Rotterdam, The Netherlands
- ITCC Consortium, Paris, France
| | - J H Beijnen
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
- Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands
| | - A Attarbaschi
- Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria
- Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Vienna, Austria
| | - A Baruchel
- Department of Pediatric Hematology, Hopital Saint Louis, Paris, France
- ITCC Consortium, Paris, France
| | - F Fagioli
- Università degli Studi di Torino, Turin, Italy
| | - T Klingebiel
- Department of Pediatrics, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - B De Moerloose
- Department of Pediatrics, Ghent University Hospital, Ghent, Belgium
| | - G Palumbo
- Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - A von Stackelberg
- Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany
| | - G J L Kaspers
- Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
- Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - A D R Huitema
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
12
|
Gargiulo P, Arenare L, Gridelli C, Morabito A, Ciardiello F, Gebbia V, Maione P, Spagnuolo A, Palumbo G, Esposito G, Della Corte CM, Morgillo F, Mancuso G, Di Liello R, Gravina A, Schettino C, Di Maio M, Gallo C, Perrone F, Piccirillo MC. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer 2021; 21:549. [PMID: 33985435 PMCID: PMC8120920 DOI: 10.1186/s12885-021-08323-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Accepted: 05/06/2021] [Indexed: 12/05/2022] Open
Abstract
Background Chemotherapy-induced neutropenia (CIN) has been demonstrated to be a prognostic factor in several cancer conditions. We previously found a significant prognostic value of CIN on overall survival (OS), in a pooled dataset of patients with advanced non-small-cell lung cancer (NSCLC) receiving first line chemotherapy from 1996 to 2001. However, the prognostic role of CIN in NSCLC is still debated. Methods We performed a post hoc analysis pooling data prospectively collected in six randomized phase 3 trials in NSCLC conducted from 2002 to 2016. Patients who never started chemotherapy and those for whom toxicity data were missing were excluded. Neutropenia was categorized on the basis of worst grade during chemotherapy: absent (grade 0), mild (grade 1–2), or severe (grade 3–4). The primary endpoint was OS. Multivariable Cox model was applied for statistical analyses. In the primary analysis, a minimum time (landmark) at 180 days from randomization was applied in order to minimize the time-dependent bias. Results Overall, 1529 patients, who received chemotherapy, were eligible; 572 of them (who received 6 cycles of treatment) represented the landmark population. Severe CIN was reported in 143 (25.0%) patients and mild CIN in 135 (23.6%). At multivariable OS analysis, CIN was significantly predictive of prognosis although its prognostic value was entirely driven by severe CIN (hazard ratio [HR] of death 0.71; 95%CI: 0.53–0.95) while it was not evident with mild CIN (HR 1.21; 95%CI: 0.92–1.58). Consistent results were observed in the out-of-landmark group (including 957 patients), where both severe and mild CIN were significantly associated with a reduced risk of death. Conclusion The pooled analysis of six large trials of NSCLC treatment shows that CIN occurrence is significantly associated with a longer overall survival, particularly in patients developing severe CIN, confirming our previous findings. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08323-4.
Collapse
Affiliation(s)
- Piera Gargiulo
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Laura Arenare
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Cesare Gridelli
- Division of Medical Oncology, Ospedale "S.G. Moscati", Contrada Amoretta, 83100, Avellino, Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Fortunato Ciardiello
- Department of Precision Medicine, Medical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Via S. Pansini 5, 80131, Naples, Italy
| | - Vittorio Gebbia
- La Maddalena Clinic for Cancer, Department Promise, Medical Oncology, Università di Palermo, 90100, Palermo, Italy
| | - Paolo Maione
- Division of Medical Oncology, Ospedale "S.G. Moscati", Contrada Amoretta, 83100, Avellino, Italy
| | - Alessia Spagnuolo
- Division of Medical Oncology, Ospedale "S.G. Moscati", Contrada Amoretta, 83100, Avellino, Italy
| | - Giuliano Palumbo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Giovanna Esposito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Carminia Maria Della Corte
- Department of Precision Medicine, Medical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Via S. Pansini 5, 80131, Naples, Italy
| | - Floriana Morgillo
- Department of Precision Medicine, Medical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Via S. Pansini 5, 80131, Naples, Italy
| | - Gianfranco Mancuso
- La Maddalena Clinic for Cancer, Department Promise, Medical Oncology, Università di Palermo, 90100, Palermo, Italy
| | - Raimondo Di Liello
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Adriano Gravina
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Clorinda Schettino
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Massimo Di Maio
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Via Magellano 1, 10028, Turin, Italy
| | - Ciro Gallo
- Medical Statistics, Università degli Studi della Campania "Luigi Vanvitelli", Via L. Armanni, 80128, Napoli, Italy
| | - Francesco Perrone
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy
| | - Maria Carmela Piccirillo
- Clinical Trials Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Via Mariano Semmola, 80131, Naples, Italy.
| |
Collapse
|
13
|
Gargiulo P, Di Liello R, Arenare L, Gridelli C, Morabito A, Ciardiello F, Gebbia V, Maione P, Spagnuolo A, Palumbo G, Esposito G, Della Corte C, Morgillo F, Mancuso G, Gravina A, Schettino C, Di Maio M, Gallo C, Perrone F, Piccirillo M. 167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)02009-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Scarabello M, Righini A, Severino M, Pinelli L, Parazzini C, Scola E, Palumbo G, Di Maurizio M, D'Errico I, Rossi A, Triulzi F, Griffiths PD. Ganglionic Eminence Anomalies and Coexisting Cerebral Developmental Anomalies on Fetal MR Imaging: Multicenter-Based Review of 60 Cases. AJNR Am J Neuroradiol 2021; 42:1151-1156. [PMID: 33707279 DOI: 10.3174/ajnr.a7062] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 12/17/2020] [Indexed: 01/25/2023]
Abstract
BACKGROUND AND PURPOSE The ganglionic eminences are transient fetal brain structures that produce a range of neuron types. Ganglionic eminence anomalies have been recognized on fetal MR imaging and anecdotally found in association with a number of neurodevelopmental anomalies. The aim of this exploratory study was to describe and analyze the associations between ganglionic eminence anomalies and coexisting neurodevelopmental anomalies. MATERIALS AND METHODS This retrospective study includes cases of ganglionic eminence anomalies diagnosed on fetal MR imaging during a 20-year period from 7 centers in Italy and England. Inclusion criteria were cavitation or increased volume of ganglionic eminences on fetal MR imaging. The studies were analyzed for associated cerebral developmental anomalies: abnormal head size and ventriculomegaly, reduced opercularization or gyration, and abnormal transient layering of the developing brain mantle. The results were analyzed using χ2 and Fisher exact tests. RESULTS Sixty fetuses met the inclusion criteria (21 females, 24 males, 15 sex unknown). Thirty-four had ganglionic eminence cavitations (29 bilateral and 5 unilateral), and 26 had increased volume of the ganglionic eminences (19 bilateral, 7 unilateral). Bilateral ganglionic eminence cavitations were associated with microcephaly (P = .01), reduced opercularization, (P < .001), reduced gyration (P < .001), and cerebellar anomalies (P = .01). Unilateral ganglionic eminence cavitations were not significantly associated with any particular feature. Bilateral increased volume of the ganglionic eminences showed an association with macrocephaly (P = .03). Unilateral increased volume was associated with macrocephaly (P = .002), abnormal transient layering (P = .001), unilateral polymicrogyria (P = .001), and hemimegalencephaly (P < .001). CONCLUSIONS Ganglionic eminence anomalies are associated with specific neurodevelopmental anomalies with ganglionic eminence cavitations and increased ganglionic eminence volume apparently having different associated abnormalities.
Collapse
Affiliation(s)
- M Scarabello
- From the Pediatric Radiology and Neuroradiology Department (M. Scarabello, A.R., C.P.), Children's Hospital V. Buzzi, Milan, Italy
| | - A Righini
- From the Pediatric Radiology and Neuroradiology Department (M. Scarabello, A.R., C.P.), Children's Hospital V. Buzzi, Milan, Italy
| | - M Severino
- Neuroradiology Department (M. Severino), Istituto Di Ricovero e Cura a Carattere Scientifico-Gaslini Children's Research Hospital, Genoa, Italy
| | - L Pinelli
- Neuroradiology Department (L.P.), Azienda Ospedaliera Spedali Civili Di Brescia, Brescia, Italy
| | - C Parazzini
- From the Pediatric Radiology and Neuroradiology Department (M. Scarabello, A.R., C.P.), Children's Hospital V. Buzzi, Milan, Italy
| | - E Scola
- Neuroradiology Department (E.S., F.T.), Istituto Di Ricovero e Cura a Carattere Scientifico-Fondazione Policlinico di Milano, Milan, Italy
| | - G Palumbo
- Radiology Department (G.P.), Azienda Ospedaliera Spedali Civili Di Brescia, Brescia, Italy
| | - M Di Maurizio
- Radiology Department (M.D.M.), Children's Hospital Meyer, Florence, Italy
| | - I D'Errico
- Neuroradiology Department (I.D.), University Hospital, Padua, Italy
| | - A Rossi
- Neuroradiology Department (M. Severino), Istituto Di Ricovero e Cura a Carattere Scientifico-Gaslini Children's Research Hospital, Genoa, Italy
| | - F Triulzi
- Neuroradiology Department (E.S., F.T.), Istituto Di Ricovero e Cura a Carattere Scientifico-Fondazione Policlinico di Milano, Milan, Italy
| | - P D Griffiths
- Academic Unit of Radiology (P.D.G.), University of Sheffield, Sheffield, UK
| |
Collapse
|
15
|
Abstract
Bloch oscillations (BOs) are a fundamental phenomenon by which a wave packet undergoes a periodic motion in a lattice when subjected to a force. Observed in a wide range of synthetic systems, BOs are intrinsically related to geometric and topological properties of the underlying band structure. This has established BOs as a prominent tool for the detection of Berry-phase effects, including those described by non-Abelian gauge fields. In this work, we unveil a unique topological effect that manifests in the BOs of higher-order topological insulators through the interplay of non-Abelian Berry curvature and quantized Wilson loops. It is characterized by an oscillating Hall drift synchronized with a topologically-protected inter-band beating and a multiplied Bloch period. We elucidate that the origin of this synchronization mechanism relies on the periodic quantum dynamics of Wannier centers. Our work paves the way to the experimental detection of non-Abelian topological properties through the measurement of Berry phases and center-of-mass displacements.
Collapse
Affiliation(s)
- M Di Liberto
- Center for Nonlinear Phenomena and Complex Systems, Université Libre de Bruxelles, CP 231, Campus Plaine, Brussels, B-1050, Belgium.
| | - N Goldman
- Center for Nonlinear Phenomena and Complex Systems, Université Libre de Bruxelles, CP 231, Campus Plaine, Brussels, B-1050, Belgium
| | - G Palumbo
- Center for Nonlinear Phenomena and Complex Systems, Université Libre de Bruxelles, CP 231, Campus Plaine, Brussels, B-1050, Belgium
| |
Collapse
|
16
|
Cena L, Mirabella F, Palumbo G, Gigantesco A, Trainini A, Stefana A. Prevalence of maternal antenatal anxiety and its association with demographic and socioeconomic factors: A multicentre study in Italy. Eur Psychiatry 2020; 63:e84. [PMID: 32892763 PMCID: PMC7576533 DOI: 10.1192/j.eurpsy.2020.82] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 06/16/2020] [Accepted: 08/27/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Maternal antenatal anxiety is very common, and despite its short- and long-term effects on both mothers and fetus outcomes, it has received less attention than it deserves in scientific research and clinical practice. Therefore, we aimed to estimate the prevalence of state anxiety in the antenatal period, and to analyze its association with demographic and socioeconomic factors. METHODS A total of 1142 pregnant women from nine Italian healthcare centers were assessed through the state scale of the State-Trait Anxiety Inventory and a clinical interview. Demographic and socioeconomic factors were also measured. RESULTS The prevalence of anxiety was 24.3% among pregnant women. There was a significantly higher risk of anxiety in pregnant women with low level of education (p < 0.01), who are jobless (p < 0.01), and who have economic problems (p < 0.01). Furthermore, pregnant women experience higher level of anxiety when they have not planned the pregnancy (p < 0.01), have a history of abortion (p < 0.05), and have children living at the time of the current pregnancy (p < 0.05). CONCLUSION There exists a significant association between maternal antenatal anxiety and economic conditions. Early evaluation of socioeconomic status of pregnant women and their families in order to identify disadvantaged situations might reduce the prevalence of antenatal anxiety and its direct and indirect costs.
Collapse
Affiliation(s)
- L. Cena
- Department of Clinical and Experimental Sciences, Section of Neuroscience, Observatory of Perinatal Clinical Psychology, University of Brescia, viale Europa 11, Brescia25123, Italy
| | - F. Mirabella
- Center for Behavioural Sciences and Mental Health, National Institute of Health, Viale Regina Elena 299, Rome00161, Italy
| | - G. Palumbo
- Center for Behavioural Sciences and Mental Health, National Institute of Health, Viale Regina Elena 299, Rome00161, Italy
| | - A. Gigantesco
- Center for Behavioural Sciences and Mental Health, National Institute of Health, Viale Regina Elena 299, Rome00161, Italy
| | - A. Trainini
- Department of Clinical and Experimental Sciences, Section of Neuroscience, Observatory of Perinatal Clinical Psychology, University of Brescia, viale Europa 11, Brescia25123, Italy
| | - A. Stefana
- Department of Clinical and Experimental Sciences, Section of Neuroscience, Observatory of Perinatal Clinical Psychology, University of Brescia, viale Europa 11, Brescia25123, Italy
| |
Collapse
|
17
|
Manzo A, Carillio G, Montanino A, Sforza V, Palumbo G, Esposito G, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Botti G, Totaro G, Muto P, Picone C, Normanno N, Morabito A. The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opin Drug Saf 2020; 19:775-783. [PMID: 32400223 DOI: 10.1080/14740338.2020.1767584] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
INTRODUCTION Atezolizumab is a humanized monoclonal antibody against PD-L1 capable of enhancing antitumor immune activity, with a demonstrated activity as single agent in patients with advanced non-small-cell lung cancer (NSCLC). AREAS COVERED This review summarizes the clinical data emerging from randomized clinical studies with atezolizumab in NSCLC and small-cell lung cancer (SCLC), focusing in particular on the efficacy and safety data regarding the combinations of atezolizumab plus chemotherapy in the IMpower studies. EXPERT OPINION A significant improvement in progression-free survival and in overall survival was observed in IMpower 130 and 150 (NSCLC non-squamous) and 133 (SCLC), with an acceptable safety profile. In particular, the most common immune-related adverse events were rash (18-28% of patients), hypothyroidism (8-15%), hepatitis (5-17%), pneumonitis (2-7%), and colitis (1.5-2.3%). The safety profile of atezolizumab in combination with chemotherapy was consistent with the known adverse events related to single-agent atezolizumab and no new adverse events were observed. Ongoing studies will evaluate the role of atezolizumab in other settings (adjuvant and neoadjuvant) and in combination with chemotherapy and radiotherapy for patients with locally advanced NSCLC and the role of predictive factors (B-FAST study).
Collapse
Affiliation(s)
- Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| | - Guido Carillio
- Department of Oncology & Hematology, Azienda Ospedaliera Pugliese-Ciaccio , Catanzaro, Italy
| | - Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| | - Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| | | | - Giovanna Esposito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| | - Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| | - Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | - Nicola Martucci
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | - Antonello La Rocca
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | - Giuseppe De Luca
- Thoracic Surgery, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | | | - Rossella De Cecio
- Pathology, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | - Gerardo Botti
- Scientific Directorate, Istituto Nazionale Tumori, "Fondazione G. Pascale" - IRCCS , Naples, Italy
| | - Giuseppe Totaro
- Radiotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS , Naples, Italy
| | - Paolo Muto
- Radiotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS , Naples, Italy
| | - Carmine Picone
- Radiology, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | - Nicola Normanno
- Cell Biology and Biotherapy, Istituto Nazionale Tumori, "Fondazione G.Pascale" - IRCCS , Napoli, Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G.Pascale"-IRCCS , Napoli, Italy
| |
Collapse
|
18
|
Palumbo G, Giovanna Esposito G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, La Manna C, Martucci N, La Rocca A, De Luca G, Piccirillo MC, De Cecio R, Perrone F, Totaro G, Muto P, Picone C, Normanno N, Morabito A. Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. Exploration of Targeted Anti-tumor Therapy 2020; 1:117-130. [PMID: 36046069 PMCID: PMC9400697 DOI: 10.37349/etat.2020.00008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 04/16/2020] [Indexed: 11/19/2022] Open
Abstract
Abstract
Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevacizumab plus erlotinib improved progression-free survival as second-line therapy in the BeTa study and as maintenance therapy in the ATLAS trial, although the benefit was modest and did not translate into an advantage in overall survival. Disappointing results were reported with oral VEGF inhibitors plus erlotinib in pretreated patients with EGFR wild type NSCLC. On the contrary, erlotinib plus bevacizumab or ramucirumab showed a clinically relevant improvement of progression-free survival in naïve patients with EGFR mutations, leading to the approval of these two regimens as first-line treatment of NSCLC patients with EGFR mutant tumors. Several clinical studies are evaluating the feasibility and activity of osimertinib plus bevacizumab or ramucirumab. However, limits that could affect its use in clinical practice are the need of an intravenous infusion for angiogenesis inhibitors, the increased incidence of treatment associated adverse events, the exclusion of patients with tumors located in central position or at risk of hemorrhage. The identification of predictive biomarkers is an important goal of research to optimize the combined use of these agents.
Keywords
Lung cancer, angiogenesis, tyrosine kinase inhibitor, erlotinib, bevacizumab
Collapse
Affiliation(s)
- Giuliano Palumbo
- Department of Oncology, Ospedale S. Maria della Pietà, Casoria, 80026 Napoli, Italy
| | | | - Guido Carillio
- Department of Oncology & Hematology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy
| | - Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
| | - Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
| | - Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
| | - Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
| | - Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Nicola Martucci
- Thoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Antonello La Rocca
- Thoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Giuseppe De Luca
- Thoracic Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Maria Carmela Piccirillo
- Clinical Trials Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Rossella De Cecio
- Pathology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Francesco Perrone
- Clinical Trials Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Giuseppe Totaro
- Radiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, 80131 Naples, Italy
| | - Paolo Muto
- Radiotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, 80131 Naples, Italy
| | - Carmine Picone
- Radiology, Istituto Nazionale Tumori “Fondazione G. Pascale”- IRCCS, 80131 Naples, Italy
| | - Nicola Normanno
- Cellular Biology and Biotherapy, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Naples, Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
| |
Collapse
|
19
|
Palumbo G, Mirabella F, Gigantesco A. Positive screening and risk factors for postpartum depression. Eur Psychiatry 2020; 42:77-85. [DOI: 10.1016/j.eurpsy.2016.11.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 11/15/2016] [Accepted: 11/19/2016] [Indexed: 11/29/2022] Open
|
20
|
Pasquale R, Forgione L, Roma C, Fenizia F, Bergantino F, Rachiglio AM, De Luca A, Gallo M, Maiello MR, Palumbo G, Morabito A, Azzaro R, Normanno N. Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. Transl Lung Cancer Res 2020; 9:61-70. [PMID: 32206554 PMCID: PMC7082281 DOI: 10.21037/tlcr.2020.01.01] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background Sequencing artifacts, clonal hematopoietic mutations of indeterminate potential (CHIP) and tumor heterogeneity have been hypothesized to contribute to the low concordance between tissue and cell-free DNA (cfDNA) molecular profiling with targeted sequencing. Methods We analyzed by targeted sequencing cfDNA from 30 healthy individuals, and cfDNA and matched tumor samples from 30 EGFR-mutant and 77 EGFR wild-type metastatic non-small-cell lung cancer (mNSCLC) patients. Discordant cases were solved by droplet digital PCR (ddPCR). Results By testing cfDNA from healthy donors, we developed an algorithm to recognize sequencing artifacts. Applying this method to cfDNA from mNSCLC patients, EGFR mutations were detected with a good sensitivity (76.7%) and specificity (97.4%). In contrast, sensitivity and specificity for KRAS variants were 61.5% and 93.8%, respectively. All EGFR and KRAS variants detected in plasma but not in tissue were confirmed by ddPCR, thus excluding sequencing artifacts. In a fraction of cases, KRAS mutations found in plasma samples were confirmed in tumor tissue suggesting tumor heterogeneity. KRAS variants were found to be more likely sub-clonal as compared with EGFR mutations, and a correlation between clonal origin and frequency of detection in plasma was found. In a case with both EGFR and KRAS variants in cfDNA, we could demonstrate the presence of the KRAS variant in tumor tissue associated with lack of response to tyrosine kinase inhibitors (TKIs). Conclusions Although sequencing artifacts can be identified in targeted sequencing of cfDNA, tumor heterogeneity and CHIP are likely to influence the concordance between plasma and tissue testing.
Collapse
Affiliation(s)
- Raffaella Pasquale
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Laura Forgione
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Cristin Roma
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Francesca Fenizia
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Francesca Bergantino
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Anna M Rachiglio
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Antonella De Luca
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Marianna Gallo
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Monica R Maiello
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Giuliano Palumbo
- Medical Oncology, Ospedale Santa Maria della Pietà, Casoria, Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Department of Hemathology, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Rosa Azzaro
- Transfusion Service, Department of Hemathology, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| | - Nicola Normanno
- Cell Biology and Biotherapy, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Via M. Semmola, Naples, Italy
| |
Collapse
|
21
|
Prefumo F, Petrilli G, Palumbo G, Sartori E, Izzi C, Pinelli L. Prenatal ultrasound diagnosis of cavitation of ganglionic eminence. Ultrasound Obstet Gynecol 2019; 54:558-560. [PMID: 30740797 DOI: 10.1002/uog.20236] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 01/26/2019] [Accepted: 02/07/2019] [Indexed: 06/09/2023]
Affiliation(s)
- F Prefumo
- Prenatal Diagnosis Unit, Department of Obstetrics and Gynaecology, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | - G Petrilli
- Department of Pathology, University of Brescia, ASST Spedali Civili di Brescia, Italy
| | - G Palumbo
- Department of Radiology, University of Brescia, Brescia, Italy
| | - E Sartori
- Department of Obstetrics and Gynaecology, University of Brescia, Brescia, Italy
| | - C Izzi
- Prenatal Diagnosis Unit, Department of Obstetrics and Gynaecology, University of Brescia, ASST Spedali Civili, Brescia, Italy
| | - L Pinelli
- Neuroradiology Unit, Pediatric Neuroradiology Section, ASST Spedali Civili, Brescia, Italy
| |
Collapse
|
22
|
Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna CL, Luca GD, Piccirillo MC, Daniele G, Cecio RD, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A. Pembrolizumab in lung cancer: current evidence and future perspectives. Future Oncol 2019; 15:3327-3336. [DOI: 10.2217/fon-2019-0073] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.
Collapse
Affiliation(s)
- Giuliano Palumbo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Guido Carillio
- Department of Oncology & Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Giuseppe De Luca
- Thoracic Surgery, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | | | - Gennaro Daniele
- Clinical Trials Unit, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Rossella De Cecio
- Pathology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Gerardo Botti
- Scientific Directorate, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Giuseppe Totaro
- Radiotherapy, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Paolo Muto
- Radiotherapy, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Carmine Picone
- Radiology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Giovanna Esposito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Nicola Normanno
- Cellular Biology & Biotherapy, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| | - Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
| |
Collapse
|
23
|
Palumbo G, Cusanno A, Garcia Romeu M, Bagudanch I, Contessi Negrini N, Villa T, Farè S. Single Point Incremental Forming and Electrospinning to produce biodegradable magnesium (AZ31) biomedical prostheses coated with porous PCL. ACTA ACUST UNITED AC 2019. [DOI: 10.1016/j.matpr.2018.11.101] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
24
|
Conte G, Lo Russo FM, Calloni SF, Sina C, Barozzi S, Di Berardino F, Scola E, Palumbo G, Zanetti D, Triulzi FM. MR imaging of endolymphatic hydrops in Ménière's disease: not all that glitters is gold. Acta Otorhinolaryngol Ital 2018; 38:369-376. [PMID: 30197428 PMCID: PMC6146579 DOI: 10.14639/0392-100x-1986] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Accepted: 02/01/2018] [Indexed: 11/23/2022]
Abstract
Ménière's disease (MD) is a chronic condition characterised by fluctuating hearing loss, intermittent vertigo, tinnitus and aural fullness. Its anatomical and pathological counterpart is represented by endolymphatic hydrops (EH). Recent development and progress in magnetic resonance (MR) imaging techniques has enabled visualisation of EH in living human subjects using a 3 Tesla (T) scanner and gadolinium-based contrast-agent (GBCA) via intravenous (IV) or intra-tympanic (IT) administration. Data emerging from the literature about MR imaging of EH in MD patients are limited, and we therefore reviewed the most common MR imaging findings in the study of the endolymphatic space in both MD and non-MD patients.
Collapse
Affiliation(s)
- G. Conte
- Neuroradiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - F. M. Lo Russo
- Postgraduation School in Radiodiagnostics, Università degli Studi di Milano, Milan, Italy
| | - S. F. Calloni
- Postgraduation School in Radiodiagnostics, Università degli Studi di Milano, Milan, Italy
| | - C. Sina
- Neuroradiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - S. Barozzi
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| | - F. Di Berardino
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
- Audiology Unit, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - E. Scola
- Neuroradiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - G. Palumbo
- Neuroradiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - D. Zanetti
- Audiology Unit, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - F. M. Triulzi
- Neuroradiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
25
|
Conte G, Milani S, Palumbo G, Talenti G, Boito S, Rustico M, Triulzi F, Righini A, Izzo G, Doneda C, Zolin A, Parazzini C. Prenatal Brain MR Imaging: Reference Linear Biometric Centiles between 20 and 24 Gestational Weeks. AJNR Am J Neuroradiol 2018. [PMID: 29519792 DOI: 10.3174/ajnr.a5574] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND AND PURPOSE Evaluation of biometry is a fundamental step in prenatal brain MR imaging. While different studies have reported reference centiles for MR imaging biometric data of fetuses in the late second and third trimesters of gestation, no one has reported them in fetuses in the early second trimester. We report centiles of normal MR imaging linear biometric data of a large cohort of fetal brains within 24 weeks of gestation. MATERIALS AND METHODS From the data bases of 2 referral centers of fetal medicine, accounting for 3850 examinations, we retrospectively collected 169 prenatal brain MR imaging examinations of singleton pregnancies, between 20 and 24 weeks of gestational age, with normal brain anatomy at MR imaging and normal postnatal neurologic development. To trace the reference centiles, we used the CG-LMS method. RESULTS Reference biometric centiles for the developing structures of the cerebrum, cerebellum, brain stem, and theca were obtained. The overall interassessor agreement was adequate for all measurements. CONCLUSIONS Reference biometric centiles of the brain structures in fetuses between 20 and 24 weeks of gestational age may be a reliable tool in assessing fetal brain development.
Collapse
Affiliation(s)
- G Conte
- From the Neuroradiology Unit (G.C.,G.P., F.T.)
| | - S Milani
- Department of Clinical Sciences and Community Health (S.M., A.Z.), Laboratory of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro,"
| | - G Palumbo
- From the Neuroradiology Unit (G.C.,G.P., F.T.)
| | - G Talenti
- Neuroradiology Unit (G.T.), Padua University Hospital, Padua, Italy
| | - S Boito
- Division of Prenatal Diagnosis (S.B.), Istituto Di Ricovero e Cura a Carattere Scientifico Fondazione Ca' Granda Ospedale Policlinico, Milan, Italy
| | - M Rustico
- Fetal Therapy Unit "Umberto Nicolini" (M.R.), Department of Woman Mother and Neonate
| | - F Triulzi
- From the Neuroradiology Unit (G.C.,G.P., F.T.)
- Department of Pathophysiology and Transplantation (F.T.), Università degli Studi di Milano, Milan, Italy
| | - A Righini
- Department of Paediatric Radiology and Neuroradiology (A.R., G.I., C.D., C.P.), Ospedale dei Bambini "V. Buzzi," Milan, Italy
| | - G Izzo
- Department of Paediatric Radiology and Neuroradiology (A.R., G.I., C.D., C.P.), Ospedale dei Bambini "V. Buzzi," Milan, Italy
| | - C Doneda
- Department of Paediatric Radiology and Neuroradiology (A.R., G.I., C.D., C.P.), Ospedale dei Bambini "V. Buzzi," Milan, Italy
| | - A Zolin
- Department of Clinical Sciences and Community Health (S.M., A.Z.), Laboratory of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro,"
| | - C Parazzini
- Department of Paediatric Radiology and Neuroradiology (A.R., G.I., C.D., C.P.), Ospedale dei Bambini "V. Buzzi," Milan, Italy
| |
Collapse
|
26
|
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F, Agostara B, Aieta M, Alabiso O, Alicicco MG, Amadori D, Amaducci L, Amiconi G, Antuzzi G, Ardine M, Ardizzoia A, Aversa C, Badalamenti G, Barni S, Basurto C, Berardi R, Bergamasco C, Bidoli P, Bighin C, Biondi E, Bisagni G, Boni C, Borgonovo K, Botta M, Bravi S, Bruzzi P, Buono G, Butera A, Caldara A, Candeloro G, Cappelletti C, Cardalesi C, Carfora E, Cariello A, Carrozza F, Cartenì G, Caruso M, Casadei V, Casanova C, Castori L, Cavanna L, Cavazzini G, Cazzaniga M, Chilelli M, Chiodini P, Chiorrini S, Ciardiello F, Ciccarese M, Cinieri S, Clerico M, Coccaro M, Comande M, Corbo C, Cortino G, Cusenza S, Daniele G, D'arco AM, D'auria G, Dazzi C, De Angelis C, de Braud F, De Feo G, De Matteis A, De Tursi M, Di Blasio A, di Lucca G, Di Lullo L, Di Rella F, Di Renzo G, Di Stefano P, Di Stefano A, Diana A, Donati S, Fabbri A, Fabi A, Faedi M, Farina G, Farris A, Febbraro A, Fedele P, Federico P, Ferraù F, Ferretti G, Ferro A, Floriani I, Forcignanò R, Forciniti S, Forestieri V, Fornari G, Frisinghelli M, Fusco V, Gallizzi G, Galvano A, Gambardella A, Gambi A, Gebbia V, Gervasi E, Ghilardi M, Giacobino A, Giardina G, Giotta F, Giraudi S, Giuliano M, Grassadonia A, Grasso D, Grosso F, Guizzaro L, Incoronato P, Incorvaia L, Iodice G, La Verde N, Labonia V, Landi G, Latorre A, Leonardi V, Levaggi A, Limite G, Lina Bascialla L, Livi L, Maiello E, Mandelli D, Marcon I, Menon D, Montedoro M, Moraca L, Moretti A, Morritti MG, Morselli P, Mura A, Mura S, Musacchio M, Muzio A, Natale D, Natoli C, Nigro C, Nisticò C, Nuzzo A, Orditura M, Orlando L, Pacilio C, Palumbo G, Palumbo R, Pasini F, Paterno E, Pazzola A, Pelliccioni S, Pensabene M, Perroni D, Pesenti Gritti A, Petrelli F, Piccirillo MC, Pinotti G, Pogliani C, Poli D, Prader S, Recchia F, Rizzi D, Romano C, Rossello R, Rossini C, Salvucci G, Sanna V, Santini A, Saracchini S, Savastano C, Scambia G, Schettini F, Schiavone P, Schirone A, Seles E, Signoriello S, Signoriello G, Silva RR, Silvestri A, Simeon V, Spagnoletti I, Tamberi S, Teragni C, Thalmann V, Thomas R, Thomas G, Tienghi A, Tinari N, Tinessa V, Tomei F, Tonini G, Torri V, Traficante D, Tudini M, Turazza M, Vignoli R, Vitale MG, Zacchia A, Zagarese P, Zanni A, Zavallone L, Zavettieri M, Zoboli A. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol 2018; 19:474-485. [PMID: 29482983 DOI: 10.1016/s1470-2045(18)30116-5] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Revised: 01/04/2018] [Accepted: 01/08/2018] [Indexed: 01/04/2023]
Abstract
BACKGROUND Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. METHODS FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. FINDINGS Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46-72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7-90·0) with the switch strategy and 89·8% (88·2-91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73-1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9-91·7) with anastrozole (124 events), 88·0% (85·8-89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3-4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3-4 adverse events occurred in less than 2% of patients in either group. INTERPRETATION 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting. FUNDING Italian Drug Agency.
Collapse
Affiliation(s)
- Sabino De Placido
- Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples, Italy
| | - Ciro Gallo
- Statistica Medica, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
| | - Michelino De Laurentiis
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy
| | - Giancarlo Bisagni
- Dipartimento di Oncologia, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Grazia Arpino
- Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples, Italy
| | | | | | - Antonio Russo
- Dipartimento di Scienze Chirurgiche, Oncologiche e Stomatologiche, Sezione di Oncologia Medica, Università di Palermo, Palermo, Italy
| | - Lucia Del Mastro
- Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova-Oncologia Medica, Ospedale Policlinico San Martino, Genoa, Italy
| | | | - Francesco Cognetti
- Divisione Oncologia Medica 1, Istituto Nazionale Tumori Regina Elena, Rome, Italy
| | - Stefania Gori
- Oncologia Medica, Ospedale Sacro Cuore Don Calabria, Negrar, Italy
| | | | | | - Domenico Amoroso
- Oncologia Medica, Ospedale della Versilia, Lido di Camaiore (LU), Istituto Toscano Tumori, Florence, Italy
| | | | - Luca Moscetti
- Dipartimento di Oncologia Medica, Ospedale Belcolle, Viterbo, Italy
| | - Filippo Montemurro
- Divisione di Oncologia Clinica Investigativa dell'Istituto di Candiolo-IRCCS, Candiolo, Italy
| | | | | | - Vito Lorusso
- Polo Oncologico, Ospedale Vito Fazzi, Lecce, Italy
| | - Adriano Gravina
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy
| | - Gabriella Moretti
- Dipartimento di Oncologia, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Rossella Lauria
- Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples, Italy
| | - Antonella Lai
- Oncologia Medica, Azienda Ospedaliera Universitaria, Sassari, Italy
| | | | - Sergio Rizzo
- Dipartimento di Scienze Chirurgiche, Oncologiche e Stomatologiche, Sezione di Oncologia Medica, Università di Palermo, Palermo, Italy
| | - Francesco Nuzzo
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy
| | - Paolo Carlini
- Divisione Oncologia Medica 1, Istituto Nazionale Tumori Regina Elena, Rome, Italy
| | - Francesco Perrone
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Affiliation(s)
- A.R.A. Haasz
- Department of Metallurgy and Materials Science University of Toronto, Toronto, Canada, M5S IA4
| | - K.T. Aust
- Department of Metallurgy and Materials Science University of Toronto, Toronto, Canada, M5S IA4
| | - W.T. Shmayda
- Ontario Hydro Technologies, 800 Kipling Avenue, Toronto, Canada, M8Z 5S4
| | - G. Palumbo
- Ontario Hydro Technologies, 800 Kipling Avenue, Toronto, Canada, M8Z 5S4
| |
Collapse
|
28
|
Conte G, Di Berardino F, Sina C, Zanetti D, Scola E, Gavagna C, Gaini L, Palumbo G, Capaccio P, Triulzi F. MR Imaging in Sudden Sensorineural Hearing Loss. Time to Talk. AJNR Am J Neuroradiol 2017; 38:1475-1479. [PMID: 28546251 DOI: 10.3174/ajnr.a5230] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 03/20/2017] [Indexed: 11/07/2022]
Abstract
Sudden sensorineural hearing loss is defined as acute hearing loss of the sensorineural type of at least 30 dB over 3 contiguous frequencies that occurs within a 72-hour period. Although many different causative factors have been proposed, sudden sensorineural hearing loss is still considered "idiopathic" in 71%-85% of cases, and treatments are empiric, not based on etiology. MR imaging implemented with a 3D FLAIR sequence has provided new insights into the etiology of sudden sensorineural hearing loss. Herein, we review the current management trends for patients with sudden sensorineural hearing loss, from the initial clinical diagnosis to therapeutic strategies and diagnostic work-up. We focused primarily on MR imaging assessment and discuss the relevance that MR imaging findings might have for patient management, pointing out different perspectives for future clinical research.
Collapse
Affiliation(s)
- G Conte
- From the Postgraduation School of Radiodiagnostics (G.C.)
| | | | - C Sina
- Neuroradiology (C.S., E.S., C.G., F.T.)
| | | | - E Scola
- Neuroradiology (C.S., E.S., C.G., F.T.)
| | - C Gavagna
- Neuroradiology (C.S., E.S., C.G., F.T.)
| | - L Gaini
- Otolaryngology (L.G., P.C.) Units, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
| | | | - P Capaccio
- Otolaryngology (L.G., P.C.) Units, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
| | - F Triulzi
- Neuroradiology (C.S., E.S., C.G., F.T.).,Department of Pathophysiology and Transplantation (F.T.), Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
29
|
Palmieri G, Ottaviano M, De Falco S, Palumbo G, Forino C, Fiorillo P, Matano E, Damiano V. AB003. OS01.03. New proposed treatment for pure red cell aplasia thymoma-related. ACTA ACUST UNITED AC 2017. [DOI: 10.21037/med.2017.ab003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
30
|
Palumbo G, Di Lorenzo G, Ottaviano M, Damiano V. The future of melanoma therapy: developing new drugs and improving the use of old ones. Future Oncol 2016; 12:2531-2534. [PMID: 27715206 DOI: 10.2217/fon-2015-0045] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- Giuliano Palumbo
- Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy
| | - Giuseppe Di Lorenzo
- Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy
| | - Margaret Ottaviano
- Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy
| | - Vincenzo Damiano
- Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy
| |
Collapse
|
31
|
Postiglione I, Barra F, Aloj SM, Palumbo G. Photodynamic therapy with 5-aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG2. Cell Prolif 2016; 49:523-38. [PMID: 27389299 DOI: 10.1111/cpr.12274] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 06/13/2016] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES In spite of high sensitivity of A549 cells (p53(+/+) ) to lethal effects of photodynamic therapy with 5-aminolaevulinic acid (5-ALA/PDT), DNA damage was observed only in H1299 cells (p53(-/-) ), suggesting that p53 may exert a protective effect. Studies on human colon adenocarcinoma cell lines HCT-116, and their cognate knockouts for p53, were not entirely consistent with the assumption above. Exploring alternative explanations for such conflicting behaviour, we observed that expression of the ATP-binding cassette G2 (ABCG2), a regulator of cell component efflux, had important effects on PDT-generated DNA injury in PC3 cells (prostate) which are p53(-/-) and positive for ABCG2. Addition of an ABCG2 inhibitor in ABCG2 positive A549 (p53(+/+) ) and PC3 (p53(-/-) ) cells eliminated resistance to DNA damage. MATERIALS AND METHODS All cell lines investigated were incubated with 5-ALA and irradiated. Effects of PDT were evaluated assessing residual cell viability, cell-cycle profiles, PpIX localization, comet assay and Western blotting. Identical measurements were made in the presence of ABCG2 inhibitor, in cells expressing the transporter. RESULTS Our data show that cell aptitude to defend its DNA from PDT-induced injury was mainly ruled by ABCG2 expression. These findings, while providing helpful information in predicting effectiveness of 5-ALA/PDT, may indicate a way to shift PDT from a palliative to a more effective approach in anti-cancer therapy.
Collapse
Affiliation(s)
- I Postiglione
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - F Barra
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - S M Aloj
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| | - G Palumbo
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
| |
Collapse
|
32
|
Fanini D, Pacitti C, Campana E, Pantaleoni G, Palumbo G, Gasbarri A. Behavioral Responses to Amphetamine Challenge following 6-Ohda Hippocampal Lesions in Rats. Int J Immunopathol Pharmacol 2016. [DOI: 10.1177/039463209200500105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The effects of 6-hydroxydopamine (6-OHDA, 8 μ g) retrograde selective lesions of bilateral dopaminergic pathways, projecting from the ventral tegmental area of Tsai (VTA-A10) to the hippocampal formation (HF), were studied through assessment of male Sprague-Dawley rats behavior, before and following amphetamine challenge (day 15 and day 30, respectively after 6-OHDA injections). Significant differences in locomotor and exploratory activities and motor coordination were evidenced between and within groups by one-way analysis of variance (ANOVA). These VTA-hippocampal dopaminergic pathway lesions may provide a morphological basis for the interpretation of the psychomotor deficits shown in this study.
Collapse
Affiliation(s)
- Donatella Fanini
- Chair of Pharmacology, Department of Internal Medicine and Public Health, University of l'Aquila, Italy
| | - C. Pacitti
- Chair of Human Physiology, Department of Science and Biomedical Technology, University of l'Aquila, Italy
| | - Elena Campana
- Chair of Human Physiology, Department of Science and Biomedical Technology, University of l'Aquila, Italy
| | - G. Pantaleoni
- Chair of Pharmacology, Department of Internal Medicine and Public Health, University of l'Aquila, Italy
| | - G. Palumbo
- Chair of Pharmacology, Department of Internal Medicine and Public Health, University of l'Aquila, Italy
| | - Antonella Gasbarri
- Chair of Human Physiology, Department of Science and Biomedical Technology, University of l'Aquila, Italy
| |
Collapse
|
33
|
Damiano V, Ottaviano M, Rescigno P, Palumbo G, Palmieri G. Effectiveness of cytotoxic agent etoposide after biological therapy in advanced thymic tumours. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e20112] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Vincenzo Damiano
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Naples, Italy
| | - Margaret Ottaviano
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Naples, Italy
| | - Pasquale Rescigno
- Institute of Cancer Research and The Royal Marsden NHS Trust Foundation, Sutton, United Kingdom
| | | | - Giovannella Palmieri
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Napoli, Italy
| |
Collapse
|
34
|
Palmieri G, Ottaviano M, Nappi L, Rescigno P, Marino M, Montella L, Micillo M, Palumbo G, Del Vecchio S, Matano E, Damiano V. Somatostatin Analogs as mainteinance therapy in heavily pretreated thymic epithelial tumors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Palmieri G, Ottaviano M, Nappi L, Rescigno P, Marino M, Montella L, Micillo M, Palumbo G, Del Vecchio S, Damiano V. Somatostatin analogs as mainteinance therapy in heavily pretreated thymic epithelial tumors. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.7581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Giovannella Palmieri
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Napoli, Italy
| | - Margaret Ottaviano
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Naples, Italy
| | - Lucia Nappi
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Naples, Italy
| | - Pasquale Rescigno
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Naples, Italy
| | - Mirella Marino
- Department of Pathology, Regina Elena Cancer Institute, Rome, Italy
| | | | | | | | | | - Vincenzo Damiano
- Department of Clinical Medicine and Surgery and Rare Tumors Reference Centre Campania Region, University, Naples, Italy
| |
Collapse
|
36
|
Arpino G, Giuliano M, De Angelis C, Di Maio M, Schettini F, Von Arx C, Riccardi F, Palumbo G, De Laurentiis M, Crispo A, Montella M, Grimaldi M, Trunfio M, Limite G, Accurso A, De Placido S. Adjuvant therapy and outcomes in patients with stage IA breast cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e11556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Massimo Di Maio
- Department of Oncology, University of Turin, AOU S. Luigi Gonzaga, Orbassano (TO), Italy
| | | | | | | | | | | | - Anna Crispo
- National Cancer Institute "Fondazione Pascale", Naples, Italy
| | | | - Maria Grimaldi
- National Cancer Institute "Fondazione Pascale", Naples, Italy
| | | | | | | | | |
Collapse
|
37
|
Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N. “Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”. Leuk Res 2015; 39:279-83. [DOI: 10.1016/j.leukres.2014.12.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 12/01/2014] [Accepted: 12/14/2014] [Indexed: 11/29/2022]
|
38
|
Locatelli F, Masetti R, Rondelli R, Zecca M, Fagioli F, Rovelli A, Messina C, Lanino E, Bertaina A, Favre C, Giorgiani G, Ripaldi M, Ziino O, Palumbo G, Pillon M, Pession A, Rutella S, Prete A. Erratum: Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the AIEOP AML-2002/01 study. Bone Marrow Transplant 2015. [DOI: 10.1038/bmt.2014.291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
39
|
Balaban V, Stauffer W, Hammad A, Afgarshe M, Abd-Alla M, Ahmed Q, Memish Z, Saba J, Harton E, Palumbo G, Marano N. Predictors of protective behaviors among American travelers to the 2009 Hajj. J Epidemiol Glob Health 2013. [PMID: 24206790 PMCID: PMC7320419 DOI: 10.1016/j.jegh.2013.12.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- V Balaban
- Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, GA, United States.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Postiglione I, Chiaviello A, Aloj SM, Palumbo G. 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy. Cell Prolif 2013; 46:382-95. [PMID: 23869760 PMCID: PMC6622218 DOI: 10.1111/cpr.12040] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2013] [Accepted: 03/29/2013] [Indexed: 01/18/2023] Open
Abstract
OBJECTIVES Often, non-small cell lung cancers (NSCLC) respond only poorly to the tyrosine kinase inhibitor (TKI) gefitinib, which targets the epidermal growth factor receptor (EGFR), these poor responders EGFRs lacking activating mutations. In this study, we have attempted to improve TKI response of NSCLC cell lines (A549 and H1299) devoid of EGFR mutations, by combination of gefitinib and 5-ALA/photodynamic therapy (PDT). MATERIALS AND METHODS Cells of the two lines were incubated with gefitinib (from 0.5 to 50 mm, for 48 h) then irradiated at doses ranging from 4 to 20 J/cm(2) ; 5-ALA concentration and incubation time were kept constant (1 mm for 3 h). We analysed cell viability, colony-forming efficiency, cell cycle parameters, proteasome and NF-κB activity and expression patterns of specific proteins, after individual or combined treatments. RESULTS Effects (antagonistic, additive or synergistic) of combination treatment were evaluated using a predictive model (combination index) for expected interactive effects and results are consistent with mutual potentiation exceeding simple additivity. Investigation of molecular mechanisms underlying cytotoxic effects indicated that combination treatment impaired proteasome function, inhibited NF-κB transcriptional activity and hampered AKT pro-survival signalling. CONCLUSIONS The results of this study show that poor response of cells devoid of EGFR activating mutations to TKIs, can be overcome by combining gefitinib with 5-ALA/photodynamic therapy (PDT).
Collapse
Affiliation(s)
- I. Postiglione
- Department of Molecular Medicine and Health BiotechnologyUniversity Federico IINaples80131Italy
| | - A. Chiaviello
- Department of Molecular Medicine and Health BiotechnologyUniversity Federico IINaples80131Italy
| | - S. M. Aloj
- Department of Molecular Medicine and Health BiotechnologyUniversity Federico IINaples80131Italy
| | - G. Palumbo
- Department of Molecular Medicine and Health BiotechnologyUniversity Federico IINaples80131Italy
- IEOS/CNR ‘G. Salvatore’Naples80131Italy
| |
Collapse
|
41
|
Gigantesco A, Palumbo G, Mirabella F, Cascavilla I. 2547 – Prevention and early intervention in postpartum depression risk. Eur Psychiatry 2013. [DOI: 10.1016/s0924-9338(13)77232-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
42
|
Cuzzola M, Latagliata R, Spiriti MA, Nobile F, Cortelezzi A, Finelli C, Sanpaolo G, Palumbo G, Breccia M, Di Raimondo F, Alimena G, Oliva E. 42 MicroRNA changes in patients with IPSS lower-risk myelodysplastic syndromes and del5q undergoing treatment with lenalidomide. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70044-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Palumbo G, King PJ, Lichtenberger PC, Aust KT, Erb U. Grain Boundary Structure Control for Intergranular Stress-Corrosion Resistance. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-238-311] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTA geometric model for intergranular stress corrosion cracking (IGSCC) is presented and used to evaluate the influence of grain boundary structure on the IGSCC resistance of polycrystalline materials. Preliminary observations regarding the structure of intergranular fracture paths in Alloy 600 C-ring specimens exposed to high temperature caustic media are noted to be consistent with the general predictions of the proposed geometric model and demonstrate that significant enhancement to bulk IGSCC resistance may be achieved through material processing considerations which result in (1) moderate increases in the frequency of structurally ‘special’ grain boundaries (i.e., interfaces close to low Σ CSL's) and (2) refinement in grain size.
Collapse
|
44
|
Abstract
ABSTRACTElectroplating is one of the most technologically advanced methods to synthesize nanophase materials both as coatings and in bulk form. This paper demonstrates the formulation of a processing “window” for nanocrystalline Co-W alloys using factorial design. The microstructural evolution from polycrystalline to nanocrystalline to amorphous Co-W microstructures is shown for electrodeposits produced from a bath containing cobalt sulphate, sodium tungstate, Rochelle salt and ammonium chloride. The effect of operating variables such as temperature and current density is discussed.
Collapse
|
45
|
El-Sherik A, Erb U, Krstic V, Szpunar B, Aus M, Palumbo G, Aust K. Effect of Porosity on Properties of Nanocrystalline Materials. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-286-173] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTThis paper discusses the effects residual porosity may have on some properties of nanocrystalline materials. The two examples considered here are Young's modulus and saturation magnetization. It will be shown that the large variations observed for these properties may be explained, at least in part, on the basis of the residual porosity in thematerials which may vary considerably depending on the production techniques used to synthesize nanostructured materials.
Collapse
|
46
|
Abstract
ABSTRACTThe thermal stability of electrodeposited nanocrystalline Ni-1.2%P and Ni-0.12%S alloys is evaluated by in-situ electron microscopy studies. Isothermal grain size versus annealing time curves at 573K and 623K show an unexpected thermal stabilization in form of a transition from rapid initial grain growth to negligible grain growth. This behaviour is discussed in terms of the various grain boundary drag mechanisms which may be operative in these alloys.
Collapse
|
47
|
Abstract
ABSTRACTThe electrical, magnetic and mechanical properties of bulk nanocrystalline nickel produced by pulse-electrodeposition are reviewed and discussed in the context of nanoprocessing as a distinct form of grain boundary engineering to develop soft magnetic materials with improved performance characteristics.
Collapse
|
48
|
Abstract
AbstractIn this study, the effect of grain size distribution on the thermal stability of electrodeposited nanocrystalline nickel was investigated by pre-annealing material such that a limited amount of abnormal grain growth was introduced. This work was done in an effort to understand the previously reported, unexpected effect, of increasing thermal stability with decreasing grain size seen in some nanocrystalline systems. Pre-annealing produced a range of grain size distributions in materials with relatively unchanged crystallographic texture and total solute content. Subsequent thermal analysis of the pre-annealed samples by differential scanning calorimetry showed that the activation energy of further grain growth was unchanged from the as-deposited nanocrystalline nickel.
Collapse
|
49
|
Abstract
ABSTRACTIntergranular degradation processes, (e.g., corrosion, stress corrosion, cracking, creep cracking) are a frequent cause of premature and unpredictable service failure of engineering components. Recent advances in (1) understanding structure-property relationships for grain boundaries, and (2) characterization techniques for grain boundaries in polycrystalline materials, have provided the means for improved component lifetime prediction, and the opportunity to engineer intergranular-degradation resistant microstructures.In this work, we present our previously developed geometric models for grain boundary structure and grain size effects on intergranular degradation susceptibility. Specific examples are presented of the successful application of the ‘grain boundary engineering’ approach to the prediction and mitigation of intergranular corrosion, stress corrosion cracking, and creep cracking in Ni-based materials.
Collapse
|
50
|
Abstract
ABSTRACTThe present work reports oii the effect of grain boundary structure on intergranular corrosion and creep by grain boundary diffusion in polycrystalline lead (Pb). “Special” boundaries characterized by low-Σ misorientations in the Coincident Site Lattice (CSL) model have been shown to exhibit resistance to grain boundary sliding and corrosion. PbCa and PbCaSn alloys having “special” grain boundary frequencies greater than 50% showed a 30 fold reduction in steady-state creep compared with corresponding as-received alloys containing 10% to 28% of low-Σ CSL boundaries in the microstructure of comparable grain size. At the same time, increasing the frequency of “special” boundaries enhanced alloy ductility with no compromize in tensile strength. Results from electrochemical corrosion tests on polarizied Pb alloys immersed in H2SO4 (S.G.=1.28) at 70°C indicate a clear correlation between the frequency of “special” boundaries and the prolifíeration of intergranular corrosion resulting in bulk weight loss from grain-dropping. Collectively, these results advocate adopting a “gram boundary design” approach in developing advanced lead-acid battery electrodes.
Collapse
|